Our top pick for
Oyster Point Pharma, Inc is a biotechnology business based in the US. Oyster Point Pharma shares (OYST) are listed on the NASDAQ and all prices are listed in US Dollars. Oyster Point Pharma employs 30 staff and has a market cap (total outstanding shares value) of USD$544.5 million.
|Latest market close||USD$20.8|
|52-week range||USD$16 - USD$41.37|
|50-day moving average||USD$21.9394|
|200-day moving average||USD$24.1375|
|Wall St. target price||USD$60.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.1637|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-09)||N/A|
|1 month (2020-12-16)||7.83%|
|3 months (2020-10-16)||-12.42%|
|6 months (2020-07-16)||-16.83%|
|1 year (2020-01-16)||-15.93%|
|2 years (2019-01-16)||N/A|
|3 years (2018-01-16)||N/A|
|5 years (2016-01-16)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-29.04%|
|Return on equity TTM||-48.48%|
|Market capitalisation||USD$544.5 million|
TTM: trailing 12 months
There are currently 785,864 Oyster Point Pharma shares held short by investors – that's known as Oyster Point Pharma's "short interest". This figure is 2.6% up from 765,601 last month.
There are a few different ways that this level of interest in shorting Oyster Point Pharma shares can be evaluated.
Oyster Point Pharma's "short interest ratio" (SIR) is the quantity of Oyster Point Pharma shares currently shorted divided by the average quantity of Oyster Point Pharma shares traded daily (recently around 52884.522207268). Oyster Point Pharma's SIR currently stands at 14.86. In other words for every 100,000 Oyster Point Pharma shares traded daily on the market, roughly 14860 shares are currently held short.
However Oyster Point Pharma's short interest can also be evaluated against the total number of Oyster Point Pharma shares, or, against the total number of tradable Oyster Point Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oyster Point Pharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Oyster Point Pharma shares in existence, roughly 30 shares are currently held short) or 0.0935% of the tradable shares (for every 100,000 tradable Oyster Point Pharma shares, roughly 94 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Oyster Point Pharma.
Find out more about how you can short Oyster Point Pharma stock.
We're not expecting Oyster Point Pharma to pay a dividend over the next 12 months.
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.